Christopher Cabell

Christopher Cabell

Fortuna: 1 M $ al 30/06/2026

57 años
Health Technology
Consumer Services
Commercial Services

Perfil

Christopher H.
Cabell
is Chief Executive Officer at Corhepta Pharmaceuticals, Inc. since 2024.
Dr. Cabell is Director at ScienceMedia, Inc. since 2020.
Dr. Cabell is Independent Director at Pulmatrix, Inc. since 2020.
Dr. Cabell is a Member of the American College of Cardiology Foundation.
Dr. Cabell is President & Head-Research & Development at Inhibikase Therapeutics, Inc. starting 2025.
Formerly, Dr. Cabell was Chief Medical Officer & Executive Vice President at Zura Bio Ltd. from 2023 to 2024.
Dr. Cabell was Chief Medical Officer & Head-Clinical Development at Emergent BioSolutions, Inc. from 2021 to 2023.
Dr. Cabell was Chief Medical Officer, Head-Research & Development at Arena Pharmaceuticals, Inc. in 2020.
Dr. Cabell was Senior VP & Head-Therapeutic Delivery Unit at Quintiles Transnational Corp.
from 2015 to 2017.
Dr. Cabell was Chief Medical & Scientific Officer at Quintiles, Inc. (California) from 2007 to 2017.
Dr. Cabell was Chief Medical & Scientific Officer at IQVIA RDS, Inc. from 2007 to 2017.
Dr. Cabell was Chief Medical & Scientific Officer at IQVIA, Inc. Formerly, Dr. Cabell was Director at Cenduit LLC.
Dr. Cabell was Director-Echocardiography Core Lab at Duke Clinical Research Institute.
Dr. Cabell was Co-Chairman at Cardiac Safety Research Consortium.
Dr. Cabell was Co-Chairman at US Food & Drug Administration.
Dr. Cabell was Associate Professor at Duke University School of Medicine.
Education includes graduate degree from Duke University, undergraduate degree from The Pennsylvania State University, and doctorate from Duke University School of Medicine.

Participaciones conocidas en empresas públicas

EmpresaFechaNúmero de accionesValoraciónFecha de valoración
15/04/2026 676.564 ( 0,51 % ) 1 M $ 30/06/2026
23/02/2026 0 ( -.--% ) - $ 30/06/2026

Cargos activos de Christopher Cabell

EmpresasCargoInicio
PULMATRIX, INC. Director/Miembro de la Junta 23/06/2020
INHIBIKASE THERAPEUTICS, INC. Presidente 21/02/2025
Director/Miembro de la Junta 18/02/2020
Corporate Officer/Principal 30/04/2009

Antiguos cargos conocidos de Christopher Cabell.

EmpresasCargoFin
ZURA BIO LIMITED Director Técnico/Científico/I+D 15/01/2024
EMERGENT BIOSOLUTIONS INC. Director Técnico/Científico/I+D 01/01/2023
ARENA PHARMACEUTICALS Director Técnico/Científico/I+D 01/12/2020
Director Técnico/Científico/I+D 01/09/2017
Director Técnico/Científico/I+D 22/07/2011
Ver el detalle de la experiencia de Christopher Cabell.

Formación de Christopher Cabell.

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Relaciones

77

Relaciones de 1er grado

18

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Empresas relacionadas

Empresas privadas18

Commercial Services

Technology Services

Health Technology

Health Services

Consumer Services

Health Technology

Consumer Services

Health Technology

Government

Health Services

Commercial Services

Technology Services

Distribution Services

Health Technology

Consumer Services

Health Technology

Cardiac Safety Research Consortium

Health Technology

  1. Bolsa de valores
  2. Insiders
  3. Christopher Cabell